Chemotherapy-induced ovarian failure (CIOF) in young women with early breast cancer (EBC).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 10068-10068 ◽  
Author(s):  
Jenny Furlanetto ◽  
Christian Thode ◽  
Martina Bassy ◽  
Carsten Denkert ◽  
Claus Hanusch ◽  
...  
Keyword(s):  
Young Women ◽  
Triple Negative ◽  
Ovarian Function ◽  
Follicle Stimulating Hormone ◽  
Time Sequence ◽  
Blood Samples ◽  
Hormone Levels ◽  
End Of Treatment ◽  
Function Table ◽  
Dose Dense

10068 Background: Women ≤45 years (yrs) treated with chemotherapy (CT) for EBC have a high risk of developing CIOF. Awareness of CIOF is essential for young women. Methods: 740 patients (pts) aged ≤45yrs treated with anthracycline or taxane-based CT for EBC from 4 German neoadjuvant/adjuvant trials were included. Blood samples were collected at baseline (N=740), end of treatment (EOT n=740), 6 (n=177), 12 (n=113), 18 (n=69), 24 (n=47) months (m) after EOT. Only samples collected in a time sequence were included. Estradiol (E2), Follicle-Stimulating Hormone (FSH) and Anti-Müllerian Hormone (AMH) were centrally assessed. CIOF was defined as FSH >12.4IU/l and E2 <52.2ng/ml and was analysed per timepoint and according to clinical and treatment-related variables. Results: Median age was 40yrs (range 21-45); 57.2% had BMI 18.5-<25, 41.1% ≥25; 32% had luminal, 35.9% HER2+, 32.0% triple-negative BC. Median hormone levels at baseline for pts <30yrs vs 30-40yrs vs ≥40yrs were: FSH 5.2IU/I vs 5.6IU/I vs 6.4IU/I; E2 101ng/l vs 86ng/l vs 88ng/l; AMH 2.14ng/ml vs 1.58ng/ml vs 0.53ng/ml. 85.7% of pts had CIOF at EOT, 62.2% at 6m, 54.0% at 12m, 43.5% at 18m, 38.3% at 24m. Similar results were observed in 47 pts with all timepoint samples available. Older vs younger pts had more frequently CIOF at EOT (≥40yrs 94.6%, 30-40yrs 82.0%, <30yrs 50.0%, p<0.001). CIOF at EOT was not influenced by BMI. CT agents impacted the rate of CIOF (p<0.001; Table 1). Higher rate of CIOF was associated with longer CT duration (12w 58.3%, 16-18w 94.5%, 24w 82.1%; p<0.001) and with dose-dense (ddEC-ddD, weekly PM(Cb), intense-dd (idd) EnPC) vs conventional dosed CT (P/nP-EC q3w, P, Cz) (94.5% vs 78.6%; p<0.001). Conclusions: The majority of young women experienced CIOF after CT for EBC. After 2 yrs 62% of the pts returned to premenopausal hormone levels. Age, CT regimen, duration and density influenced the rate of CIOF and should be taken into account when counseling young women who desire to maintain ovarian function. [Table: see text]

LRF and TRF test during long-term danazol treatment: increase of the LH and FSH responses but decrease of the prolactin and TSH responses

1983 ◽  
Vol 104 (1) ◽  
pp. 1-5 ◽  
Author(s):  
J. Leppäluoto ◽  
L. Rönnberg ◽  
P. Ylöstalo
Keyword(s):  
Clinical Symptoms ◽  
Follicular Phase ◽  
Blood Samples ◽  
Hormone Levels ◽  
Coefficients Of Variation ◽  
The Mean ◽  
Thyroid Hormone Levels ◽  
Low Serum

Abstract. Seven patients suffering from severe endometriosis were treated with danazol 200 mg × 3 daily for 6 months. Clinical symptoms were alleviated and menses disappeared in response to the treatment. After cessation of the treatment the menstrual bleedings returned in 1–3 months. Blood samples for determination of gonadotrophins, prolactin (Prl), oestradiol (E2), progesterone, thyroid hormones and thyrotrophin in radioimmunoassays were taken and a combined TRF and LRF test carried out in the follicular phase before treatment, at the 6th month of treatment and after reappearance of the first menses. There were no statistically significant changes in the basal levels of serum FSH, LH or TSH during the danazol treatment. Neither was there any change in episodic secretions of FSH, LH or Prl, as determined by the mean coefficients of variation of the hormone levels in seven consecutive samples taken at 20 min intervals. On the other hand, serum E2, Prl and thyroid hormone levels were significantly decreased in the 6th month of treatment. In the TRF-LRF test the responses of serum FSH and LH were significantly higher and those of serum Prl and TSH significantly lower during danazol treatment than before. Prl responses remained lowered after the treatment. It appears that low serum oestrogen levels, induced by the danazol treatment, sensitize the pituitary gonadotrophs to exogenous LRF, but make the sensitivity of thyrotrophs and lactotrophs lower to exogenous TRF. These results thus indicate that danazol does not make the pituitary gonadotrophs insensitive to LRF, but danazol may rather inhibit the secretion of hypothalamic LRF.

scholarly journals Pesticide Exposure Alters Follicle-Stimulating Hormone Levels in Mexican Agricultural Workers

2005 ◽  
Vol 113 (9) ◽  
pp. 1160-1163 ◽  
Author(s):  
Rogelio Recio ◽  
Guadalupe Ocampo-Gómez ◽  
Javier Morán-Martínez ◽  
Victor Borja-Aburto ◽  
Malaquías López-Cervantes ◽  
...  
Keyword(s):  
Pesticide Exposure ◽  
Follicle Stimulating Hormone ◽  
Agricultural Workers ◽  
Hormone Levels ◽  
Stimulating Hormone

Follicle-stimulating hormone levels in female workers exposed to urban pollutants

2011 ◽  
Vol 21 (6) ◽  
pp. 391-401 ◽  
Author(s):  
Manuela Ciarrocca ◽  
Tiziana Caciari ◽  
Barnaba Giuseppina Ponticiello ◽  
Pier Agostino Gioffrè ◽  
Gianfranco Tomei ◽  
...  
Keyword(s):  
Follicle Stimulating Hormone ◽  
Hormone Levels ◽  
Female Workers ◽  
Urban Pollutants ◽  
Stimulating Hormone

Correlation of antimüllerian hormone and baseline follicle-stimulating hormone levels

2009 ◽  
Vol 91 (6) ◽  
pp. 2616-2619 ◽  
Author(s):  
Tomer Singer ◽  
David H. Barad ◽  
Andrea Weghofer ◽  
Norbert Gleicher
Keyword(s):  
Follicle Stimulating Hormone ◽  
Hormone Levels ◽  
Antimullerian Hormone ◽  
Antimüllerian Hormone ◽  
Stimulating Hormone

Breast Cancer in Young Women

2019 ◽  
Author(s):  
Lisa A Newman
Keyword(s):  
Breast Cancer ◽  
Young Women ◽  
Triple Negative ◽  
Breast Conserving Surgery ◽  
The United States ◽  
Population Based ◽  
Incidence Rates ◽  
Disease Stage ◽  
Locoregional Therapy ◽  
Key Words Breast

The perception that breast cancer in young women is a growing problem in the United States is based on the fact that young women represent a demographic that has enlarged substantially over the past few decades. Population-based data actually reveal relatively stable incidence rates for breast cancer among women in the premenopausal age range. Young women are more likely to be diagnosed with biologically aggressive phenotypes such as triple-negative and HER2/neu-overexpressing breast cancer. Outcomes are optimized by treatment plans focusing on disease stage and targeted to phenotype. Locoregional therapy for breast cancer in young women should be based on patient preferences and disease pattern (as in older patients); young women with breast cancer can be managed safely with breast-conserving surgery. This review contains 3 figures, 2 tables, and 50 references. Key Words: breast cancer, fertility, ovarian suppression, premenopausal, young women; triple negative breast cancer

LUTEINIZING HORMONE LEVELS IN PLASMA AND URINE IN WOMEN DURING NORMAL MENSTRUAL CYCLES AND IN WOMEN TAKING COMBINED CONTRACEPTIVES OR CHLORMADINONE ACETATE

1969 ◽  
Vol 43 (4) ◽  
pp. 617-624 ◽  
Author(s):  
A. HILARY ORR ◽  
MAX ELSTEIN
Keyword(s):  
Oral Contraceptive ◽  
Luteinizing Hormone ◽  
Young Women ◽  
Menstrual Cycles ◽  
Hormone Levels ◽  
Chlormadinone Acetate ◽  
Combined Oral Contraceptive ◽  
Low Dosage ◽  
Made In

SUMMARY Radioimmunoassay measurements of luteinizing hormone (LH) levels were made in urine and plasma throughout normal menstrual cycles and cycles when either a combined oral contraceptive or low dosage continuous chlormadinone acetate were being taken by healthy young women. The typical mid-cycle ovulatory increase of LH was suppressed in the cycles when the combined contraceptive preparations were taken but was present in the majority of cycles during the administration of continuous chlormadinone acetate.

Effects of plasma amino acid and hormone levels on renal hemodynamics in humans

1988 ◽  
Vol 255 (3) ◽  
pp. F444-F449 ◽  
Author(s):  
P. Castellino ◽  
C. Giordano ◽  
A. Perna ◽  
R. A. DeFronzo
Keyword(s):  
Growth Hormone ◽  
Amino Acid ◽  
Acid Solution ◽  
Growth Hormone Secretion ◽  
Renal Hemodynamics ◽  
Time Sequence ◽  
Plasma Amino Acid ◽  
Base Line ◽  
Amino Acid Solution ◽  
Hormone Levels

The effect of plasma amino acid and hormone (insulin, glucagon, and growth hormone) levels on renal hemodynamics was studied in 18 healthy subjects. The following four protocols were employed: study 1, a balanced amino acid solution was infused for 3 h to increase plasma amino acid concentrations two to three times base line; study 2, the same amino acid solution was infused with somatostatin (SRIF) and infusions of insulin, glucagon, and growth hormone were concomitantly administered to replace the time sequence of increase in peripheral concentrations of these hormones as observed during study 1; study 3, the same amino acid infusion was administered with SRIF plus infusions of insulin, glucagon, and growth hormone to maintain plasma hormone concentrations constant at the basal level; study 4, SRIF was infused with insulin, glucagon, and growth hormone to reproduce the time sequence of increase of these hormones as observed in study 1; amino acids were not infused in this study. During study 1, glomerular filtration rate (GFR) and renal plasma flow (RPF) rose by 19 and 21%, respectively. During study 2 both the time sequence of and magnitude of rise in GFR and in RPF were similar to the changes observed during study 1. In studies 3 and 4 neither RPF nor GFR changed significantly from base line. These results indicate that 1) hyperaminoacidemia stimulates insulin/glucagon/growth hormone secretion and causes a modest rise in GFR and RPF; and 2) if hyperaminoacidemia is created while maintaining basal hormone levels constant or if plasma insulin/glucagon/growth hormone levels are increased while maintaining the plasma amino acid concentration at basal levels, neither RPF nor GFR rise.(ABSTRACT TRUNCATED AT 250 WORDS)

Sign in / Sign up

Export Citation Format

Share Document